Acalabrutinib price

Acalabrutinib (Acalabrutinib) is an oral small molecule targeted drug that belongs to the class of brutinib (BTK) inhibitors. It is primarily used to treat B-cell lymphoma, particularly in adults with chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL).

Acotinib has been launched in China, but it has not yet been included in medical insurance. Since it has just been launched, it is still difficult for patients to purchase it domestically. They need to purchase acotinib through overseas channels. The cheaper ones abroad are mainly generic drugs, mainly Bangladeshi generic drugs. The price is around 6,000 to 7,000, and the ingredients of original drugs and generic drugs are basically the same.

As a BTK inhibitor, acotinib blocks the signaling pathway of B cells by inhibiting the Bruton tyrosine kinase in B cells, thereby reducing the survival and reproduction of leukemia cells. This specific targeting mechanism allows acotinib to more effectively intervene in the proliferation of tumor cells, alleviate patients' symptoms, and improve survival rates.

Compared with traditional chemotherapy methods, acotinib has lower toxic side effects and can target malignant cells more accurately and reduce the impact on normal cells. This also allows patients to better maintain their quality of life while undergoing treatment.

Clinical study data show that acotinib has achieved significant efficacy in the treatment of CLL and SLL and has become an important treatment option for patients with B cell lymphoma. However, patients still need to monitor closely and follow their doctor's recommendations when using acotinib, as different patients' physical conditions and conditions may vary and require individualized treatment plans.